髓系白血病
脱甲基酶
CEBPA公司
癌症研究
化学
医学
表观遗传学
转录因子
生物化学
基因
作者
Ze-Hao Fang,Suying Zheng,Weiying Feng
出处
期刊:PubMed
日期:2023-06-01
卷期号:31 (3): 902-906
标识
DOI:10.19746/j.cnki.issn.1009-2137.2023.03.042
摘要
Obesity-associated protein (FTO) is an important m6A demethylase that regulates RNA methylation modification and can promote the proliferation of acute myeloid leukemia(AML) cells. FTO regulates the methylation level of AML through multiple cellular signaling pathways such as FTO/RARA/ASB2, FTO/m6A/CEBPA, and PDGFRB/ERK, and participates in the occurrence, development, treatment and prognosis of AML. At present, studies have found that a variety of inhibitors targeting FTO have shown good anti-leukemia effects, and the study of FTO will provide new ideas for the treatment of AML. This review focus on the mechanism of action of FTO in AML and the research progress of FTO inhibitors in AML.m6A去甲基化酶FTO及其抑制剂在急性髓系白血病中的研究进展.肥胖相关蛋白(FTO)是一种重要的调控 RNA 甲基化修饰的m6A去甲基化酶,能促进急性髓细胞白血病(AML)细胞的增殖。FTO通过FTO/RARA/ASB2、FTO/m6A/CEBPA、PDGFRB/ERK等多种细胞信号通路调控AML的甲基化水平,参与AML的发生、发展、治疗以及预后。目前有研究发现,多种靶向FTO的抑制剂表现出良好的抗白血病作用,FTO的研究将为AML的治疗提供新的思路。本文就FTO在AML中的作用机制以及FTO抑制剂在AML的最新研究进展作一综述。.
科研通智能强力驱动
Strongly Powered by AbleSci AI